Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
Brenda M HuppkeMarie ReinertHannah Hummel-AbmeierWiebke StarkJutta GärtnerPeter HuppkePublished in: Neurology (2023)
The results of this study have three important implications: Firstly, pre-treatment sNfL levels are a valuable biomarker for underlying disease activity in paediatric MS patients. Secondly, pre-treatment sNfL levels in pediatric MS patients have predictive value for response to first line therapy and the necessity of future therapy escalation. Thirdly, high sNfL levels during a relapse are associated with poor recovery in this age group.
Keyphrases
- multiple sclerosis
- end stage renal disease
- disease activity
- newly diagnosed
- ejection fraction
- systemic lupus erythematosus
- rheumatoid arthritis
- mass spectrometry
- prognostic factors
- peritoneal dialysis
- ms ms
- intensive care unit
- randomized controlled trial
- rheumatoid arthritis patients
- mesenchymal stem cells
- open label
- juvenile idiopathic arthritis
- cell therapy
- smoking cessation
- combination therapy
- current status